Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
10/17/2011
Trade Name:
Reyataz
Generic or Proper Name (*):
atazanavir
Indications Studied:
Treatment of HIV - 1 infection
Therapeutic Category:
Antiviral
Ages Studied:
91 days - 21 years
Study #:
1
Study Type:
Safety/Pharmacokinetic
Study Design:
Open Label/Traditional Pharmacokinetic
No Patients:
105
No Centers:
36
No Countries:
2
BPCA(B), PREA(P):
B, P
Unknown:
0
Countries:
North America, including Puerto Rico and, South Africa
-
-